AlfaCell Platform Cell Lines Achieve Regulatory Compliance with NMPA Approval and FDA IND Clearance

Antibody drugs, as a new field in cancer treatment, have played an important role in the treatment of various major diseases such as tumor immunotherapy, autoimmune diseases, malignant hematological disorders, and cardiovascular and cerebrovascular diseases. They represent one of the most promising directions in life sciences and medical development in recent years. However, with the rise of the industry, an increasing number of antibody drug companies have faced significant challenges during the drug registration application phase due to issues like incomplete data and other traceability problems, severely delaying the progress of drug development projects. Additionally, some clients are subject to on-site inspections of cell synthesis suppliers during the review of their registration applications.

After GBB released several case tweets recently, it received a lot of feedback from customers and fans, some of whom paid more attention.Compliance of AlfaCell Platform Site-Specific Integration Cell Lines in Regulatory Submissions in China and the US, includingWhether there are approved cases, FTO test reports, genome sequencing, DMF filings, ISO quality management systems, etc.

The AlfaCell platform has obtained Drug Master File (DMF) registration with the FDA, passed the ISO9001:2015 quality management system certification, and has helped clients gain approval from the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA) for Investigational New Drug (IND) applications.And has initiated clinical trials.This article fromPatents and Authorization,Process inspection, approval filing, quality management system, and other aspects are answered one by one to explain the compliance of the AlfaCell platform cell line from Great Bay Bio.

Patents and Licenses

Great Bay Bio has proactively established a patent matrix in China and overseas for plasmids, sites, and AI technologies related to the AlfaCell platform’s targeted integration cell lines.Systematically enhance technical barriers to protect the market competitiveness, bargaining power, and risk response capabilities of clients' products.

▲AlfaCell PlatformPatent Matrix

At the same time, the cell line of the AlfaCell platform has completed the FTO report.(Freedom to Operate, FTO Report is a type of intellectual property risk assessment document. Amid the global trend of strengthening intellectual property protection, an FTO report not only analyzes whether there are risks of infringing on others' patents or other intellectual property during the commercialization of specific technologies or products in the target market but also supports the formulation of business strategies). The conclusion of the FTO report for the AlfaCell platform shows that all the platform's labeled technologies can be freely implemented in both China and the US, including plasmid components used for protein production, integration sites in CHO cells, and gene cassettes used for expressing monoclonal antibodies or fusion proteins.

In addition, GBB's cell line has been authorized under a co-licensing model.Allow the cell lines of Great Bay Bio to be transferred to non-affiliated companies, avoiding the risk of infringement related to the origin of the cell lines.

Process Testing

Great Bay BioWhole-genome sequencing of the mother cell confirmed that there was fluorescence at only one site on the genome, with no residual fluorescent protein gene or transfection enzyme present.

Great Bay BioShenzhen Taily Biotechnology Co., Ltd., a wholly-owned subsidiary, has passed the ISO9001:2015 Quality Management System certification. This certification marks that the company’s quality management and service level meet international advanced standards and can continuously provide high-quality delivery to customers in the global life science field.The company has established an efficient and strict cell line quality management system in accordance with the biopharmaceutical declaration rules, providing complete and standardized experimental record organization and writing that meet the requirements for biopharmaceutical declarations. This includes information on reagents and consumables, equipment details, full experimental processes and results, etc., ensuring compliance, authenticity, reliability, and traceability of the production process. It provides R&D enterprises with cell line compliance reports that meet IND/NDA declaration standards, fulfilling the requirements for project submissions.